Dexamethasone-induced cardioprotection: A role for the phosphatase MKP-1?

Life Sciences

Volumn 84, Issue 23-24, 2009, Pages 838-846

  Fan, W J ^a   Genade, S ^a   Genis, A ^a   Huisamen, B ^a   Lochner, A ^a  

^a Faculty of Health Sciences   (South Africa)

Author keywords

Dexamethasone; ERK42 44; Ischaemia reperfusion; Isolated rat heart; MKP 1 expression; p38 MAPK; PKB Akt

Indexed keywords

DEXAMETHASONE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATASE; PHOSPHATASE MKP 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEART; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; UPREGULATION; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; DEXAMETHASONE; DUAL SPECIFICITY PHOSPHATASE 1; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 65649131957     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.03.014     Document Type: Article

References (57)

1. Amsterdam A., Tajima K., and Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochemical Pharmacology 64 5-6 (2002) 843-850
2. Barzilai D., Plavnick J., Hazani A., Einath R., Kleinhaus N., and Kauter Y. Use of hydrocortisone in the treatment of acute myocardial infarction: summary of a clinical trial of 446 patients. Chest 61 5 (1972) 488-491
3. Bassi R., Heads R., Marber M.S., and Clark J.E. Targetting p38-MAPK in the ischaemic heart: kill or cure?. Current Opinion in Pharmacology 8 2 (2008) 141-146
4. Bell J.R., Eaton P., and Shattock M.J. Role of p38-mitogen-activated protein kinase in ischaemic preconditioning in rat heart. Clinical and Experimental Pharmacology and Physiology 35 2 (2008) 126-134
5. Bokemeyer D., Lindemann M., and Kramer H.J. Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. Hypertension 32 4 (1998) 661-667
6. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye bindings. Analytical Biochemistry 72 (1976) 248-254
7. Cato A.C., Nestl A., and Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Science's STKE: signal transduction knowledge environment RE9 (2002)
8. Croxtall J.D., Choudhury Q., and Flower R.J. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription independent mechanism. British Journal of Pharmacology 130 2 (2000) 289-298
9. Engelbrecht A.M., Engelbrecht P., Genade S., Niesler C., Page C., Smuts M., and Lochner A. Long-chain polyunsaturated fatty acids protect the heart against ischaemia/reperfusion-induced injury via a MAPK-dependent pathway. Journal of Molecular and Cellular Cardiology 39 6 (2005) 940-954
10. Engelbrecht Y., de Wet H., Horsch K., Langeveldt C.R., Hough F.S., and Hulley P.A. Glucocorticoids induce rapid upregulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144 2 (2003) 412-422
11. Feng Z., Marti A., Jehn B., Altermatt H.J., Chicaiza G., and Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. Journal of Cell Biology 131 4 (1995) 1095-1103
12. Franklin C.C., Srikanth S., and Kraft A.S. Conditional expression of mitogen-activated protein kinase phosphatase-1, MPK-1, is cytoprotective against UV-induced apoptosis. Proceedings of the National Academy Sciences of the United States of America 95 6 (1998) 3014-3019
13. Gascoyne D.M., Kypta R.M., and Vivanco M.M. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xl. Journal of Biological Chemistry 278 20 (2003) 18022-18029
14. Gonzalez M.V., Gonzalez-Sancho J.M., Caelles C., Munoz A., and Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Letters 459 2 (1999) 272-276
15. 2: Role in cell survival following oxidant injury. Journal of Biological Chemistry 271 8 (1996) 4138-4142
16. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., Hsieh C.M., Chui D.S., Thomas K.L., Prorock A.J., Laubach V.E., Moskowitz M.A., French B.A., Ley K., and Liao J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Medicine 8 5 (2002) 473-479
17. Hammerman H., Schoen F.J., Braunwald E., and Kloner R.A. Drug-induced expansion of infarct: morphological and functional correlations. Circulation 69 3 (1984) 611-617
18. Hillier S.G., and Tetsuka M. An anti-inflammatory role for glucocorticoids in the ovaries?. Journal of Reproductive Immunology 39 1-2 (1998) 21-27
19. Hutter D., Chen P., Barnes J., and Liu Y. Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation. Biochemical Journal 352 Pt 1 (2000) 155-163
20. Juhasz B., Der P., Turoczi T., Bacskay I., Varga E., and Tosaki A. Preconditioning in intact and previously diseased myocardium: laboratory or clinical dilemma?. Antioxidants and Redox Signaling 6 2 (2004) 325-333
21. Kaiser R.A., Bueno O.F., Lips D.J., Doevendans P.A., Jones F., Kimball T.F., and Molkentin J.D. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. Journal of Biological Chemistry 279 15 (2004) 15524-15530
22. Kaljusto M.L., Stensløkken K.O., Mori T., Panchenko A., Frantzen M.L., Valen G., and Vaage J. Preconditioning effects of steroids and hyperoxia on cardiac ischemia-reperfusion injury and vascular reactivity. European Journal of Cardio-Thoracic Surgery 33 3 (2008) 355-363
23. Kannengieser G.J., Opie L.H., and Van der Werff T.J. Impaired cardiac work and oxygen uptake after reperfusion of regionally ischaemic myocardium. Journal of Molecular and Cellular Cardiology 11 1 (1979) 197-207
24. Kassel O., Sancono A., Krätzschmar J., Kreft B., Stassen M., and Cato A.C. Glucocorticoids inhibit MAPkinase via increased expression and decreased degeneration of MKP-1. EMBO Journal 20 24 (2001) 7108-7116
25. Keyse S.M., and Emslie E.A. Oxidative stress and heat shock induce a human gene encoding protein-tyrosine phosphatases. Nature 359 6396 (1992) 644-647
26. Laderoute K.R., Mendonca H.L., Calaoagan J.M., Knapp A.M., Giaccia A.J., and Stork P.J. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-jun N-terminal protein kinase activity. Journal of Biological Chemistry 274 18 (1999) 12890-12897
27. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., and Clark A.R. Dexamethasone causes sustained expression of mitogen activated protein kinase (MAPK) phosphatase-1 and phosphatase-mediated inhibition of MAPK p38. Molecular and Cellular Biology 22 22 (2002) 7802-7811
28. Lasa M., Brook M., Saklatvala J., and Clark A.R. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Molecular and Cellular Biology 21 3 (2001) 771-780
29. Lefer A.M., Crossley K., Grigonis G., and Lefer D.J. Mechanism of the beneficial effect of dexamethasone on myocardial cell integrity in acute myocardial ischaemia. Basic Research Cardiology 75 2 (1980) 328-339
30. Leppö S., and Sistonen L. Heat shock response-pathophysiological implications. Annals of Medicine 29 1 (1997) 73-78
31. Libby P., Maroko P.R., Bloor C.M., Sobel B.E., and Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. Journal of Clinical Investigation 52 3 (1973) 599-607
32. Ma X.L., Kumar S., Gao F., Louden C.S., Lopez B.L., Christopher T.A., Wang C., Lee J.C., Feuerstein G.Z., and Yue T.L. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99 13 (1999) 1685-1691
33. Mackay K., and Mochley-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. Journal of Biological Chemistry 274 10 (1999) 6272-6279
34. Marais E., Genade S., Huisamen B., Strijdom J.G., Moolman J.A., and Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated by attenuated p38 MAPK activity during sustained ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology 33 4 (2001) 769-778
35. Marais E., Genade S., Salie R., Huisamen B., Maritz S., Moolman J.A., and Lochner A. The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacologic preconditioning. Basic Research in Cardiology 100 1 (2005) 35-47
36. Martin J.L., Avkiran M., Quinlan R.A., Cohen P., and Marber M.S. Antiischemic effects of SB203580 are mediated through the inhibition of p38 (alpha) mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circulation Research 89 9 (2001) 750-752
37. Metzler B., Hu Y., Sturm G., Wick G., and Xu Q. Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells. Journal of Biological Chemistry 273 50 (1998) 33320-33326
38. Mocano M., Baxter G.F., Yue Y., Critz S.D., and Yellon D.M. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in the rat heart but timing of administration is critical. Basic Research in Cardiology 95 6 (2000) 472-478
39. Moolman J.A., Hartley S., Marais E., Van Wyk J., Genade S., and Lochner A. Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovascular Drugs and Therapy 20 1 (2006) 13-25
40. Morimoto R.I., Kline M.P., Bimston D.N., and Cotto J.J. The heat shock response: regulation and function of heat shock proteins and molecular chaperones. Essays in Biochemistry 32 (1997) 17-29
41. Morizane S., Sano M., Moriyama H., Matsuhashi T., Tokudome S., Shimura K., Katayama K., Suzuki T., and Fukuda K. Glucocorticoid protects the heart from ischemia/reperfusion injury via activation of PGD2 biosynthesis. Journal of Molecular and Cellular Cardiology 45 Supplement 1 (2008) S14
42. Pecci A., Scholz A., Pelster D., and Beato M. Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. Journal of Biological Chemistry 272 18 (1997) 11791-11798
43. Rider L.G., Hirasawa N., Santini F., and Beaven M.A. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. Journal of Immunology 157 6 (1996) 2373-2380
44. Sanada S., Kitakaze M., Papst P.J., Hatanaka K., Asanuma H., Aki T., Shinozaki Y., Ogita H., Node K., Takashima S., Asakura M., Yamada J., Fukushima T., Ogai A., Kuzuya T., Mori H., Terada N., Yoshida K., and Hori M. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circulation Research 88 2 (2001) 175-180
45. Shalom-Barack T., Quach J., and Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappa B. Journal of Biological Chemistry 273 42 (1998) 27467-27473
46. Sholter D.E., and Armstrong P.W. Adverse effects of corticosteroids on the cardiovascular system. Canadian Journal of Cardiology 16 4 (2000) 505-511
47. Spath J.A., and Lefer A.M. Effects of dexamethasone on myocardial cells in the early phase of myocardial infarction. American Heart Journal 90 1 (1975) 50-55
48. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Research in Cardiology 97 4 (2002) 276-285
49. Stenslokken K.-O., Rutkovskiy A., Kaljusto M.-I., Hafstad A.D., Larsen T.S., and Vaage J. Inadvertent phosphorylation of survival kinases in isolated perfused hearts: a word of caution. Basic Research in Cardiology (2009) Electronic publication ahead of print
50. Tanoue T., Moriguchi T., and Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP5. Journal of Biological Chemistry 274 28 (1999) 19949-19956
51. Theodosiou A., Smith A., Gillieron C., Arkinstall S., and Ashworth A. MKP5, a new member of the MAP kinase phosphatase family which selectively dephosphorylates stress-activated kinases. Oncogene 18 50 (1999) 6981-6988
52. Valen G., Kawakami T., Tähepôld P., Dumitrescu A., Löwbeer C., and Vaage J. Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72. American Journal of Physiology 279 2 (2000) H836-H843
53. Varga E., Nagy N., Lazar J., Czifra G., Bak I., Biro T., and Tosaki A. Inhibition of ischemia/reperfusion-induced damage by dexamethasone in isolated working rat hearts: the role of cytochrome C release. Life Sciences 75 20 (2004) 2411-2423
54. Weinbrenner C., Liu C.S., Cohen M.V., and Downey J.M. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. Journal of Molecular and Cellular Cardiology 29 9 (1997) 2383-2391
55. Wu J.J., and Bennet A.M. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress responsive MAP kinase and cell survival signaling. Journal of Biological Chemistry 280 16 (2005) 16461-16466
56. Yamamoto M., Fukuda K., Miura N., Suzuki R., Kido T., and Komatsu Y. Inhibition by dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: a possible association with Bcl-xL induction. Hepatology 27 4 (1998) 959-966
57. 2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils. Clinical and Experimental Immunology 122 1 (2002) 20-27